Showing results (181-190 of 280) with videos related to

Sort By:
Pageof 28
The New England Journal of Medicine|May 30, 2020
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate CancerNeal D Shore, Fred Saad, Michael S Cookson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2024
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or EnzalutamideSusan Halabi, Siyuan Guo, Joseph J Park, et al.
Prostate Cancer and Prostatic Diseases|April 14, 2019
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patientsEda K Holl, Megan A McNamara, Patrick Healy, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2017
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancerAndrew J Armstrong, Susan Halabi, Patrick Healy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2018
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC StudyDaniel J George, Jean-François Martini, Michael Staehler, et al.
Journal for Immunotherapy of Cancer|February 25, 2022
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trialScott S Tykodi, Lucio N Gordan, Robert S Alter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytesRobert H Vonderheide, Susan M Domchek, Joachim L Schultze, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancerRyan E Fecteau, Bridget F Koontz, Karen E Hoffman, et al.
Cancer|May 29, 2023
Experience with the US health care system for Black and White patients with advanced prostate cancerEmily M Rencsok, Konrad H Stopsack, Natalie Slopen, et al.
Future Oncology (London, England)|May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocolsNeal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
Pageof 28